TP53 and ovarian serous adenocarcinoma: A phase II clinical trial (NCT03268382) evaluated the efficacy of APR-246 combined with PLD in patients with platinum-resistant recurrent high-grade serous ovarian cancer (HGSOC) harboring TP53 mutations.